Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS)
CNY 37.17
(0.38%)
CNY 37.17
(0.38%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.08 Billion | 837.37 Million | 366.53 Million | 428.16 Million | 489.59 Million | 289.21 Million |
| Net Income | 800.91 Million | 375.27 Million | 213.02 Million | 420.66 Million | 317.37 Million | 218.08 Million |
| Depreciation & Amortization | 61.74 Million | 69.24 Million | 81.44 Million | 77.62 Million | 76.78 Million | 76.52 Million |
| Deferred income taxes | -55.86 Million | -5.73 Million | -29.76 Million | -2.57 Million | 4.65 Million | -12.71 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -105.17 Million | 36.94 Million | -249.21 Million | 7.05 Million | 95.17 Million | -92.93 Million |
| Other non-cash items | 611.05 Million | 355.91 Million | 321.26 Million | -77.18 Million | 263.55 Thousand | 87.53 Million |
| Investing Cash Flow | -848.38 Million | -561.24 Million | -740.8 Million | 69.16 Million | -223.49 Million | -14.23 Million |
| Investments in PPE | -21.68 Million | -101.96 Million | -425.57 Million | -221.29 Million | -48.99 Million | -23.36 Million |
| Acquisitions | 2.75 Million | 112.42 Thousand | 16.78 Million | 14.51 Thousand | 17.32 Thousand | 1.24 |
| Investment purchases | -3.82 Billion | -2.02 Billion | -685 Million | -1.12 Billion | -1.02 Billion | -690 Million |
| Sales/Maturities of investments | 2.99 Billion | 1.56 Billion | 352.9 Million | 1.4 Billion | 848.39 Million | 698.9 Million |
| Other Investing Activities | 1.00 | 1.05 | 89.04 Thousand | 2.82 Million | -2.91 Million | 223.4 Thousand |
| Financing Cash Flow | -485.89 Million | -145.36 Million | 376.66 Million | -178.42 Million | -152.52 Million | -69.15 Million |
| Debt repayment | -13.77 Million | -534.26 Million | -52.68 Million | -10.4 Million | - | - |
| Dividends payments | -482.98 Million | -83.8 Million | -126.44 Million | -187.72 Million | -66.45 Million | -69.15 Million |
| Common Stock Repurchased | - | - | - | - | -85 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 10.86 Million | 487.07 Million | 561.84 Million | 20.8 Million | -0.97 | - |
| Accounts receivables | -237.88 Million | 22.81 Million | -317.09 Million | -21.69 Million | 58.57 Million | -94.83 Million |
| Accounts payables | 147.4 Million | 38.73 Million | 164.84 Million | 28 Million | 45.01 Million | -9.77 Million |
| Inventory | -16.55 Million | -18.86 Million | -67.19 Million | 3.32 Million | -13.07 Million | 24.38 Million |
| Other working capital | 1.86 Million | -5.73 Million | -29.76 Million | -2.57 Million | 4.65 Million | -117.31 Million |
| Cash at beginning of period | 929.28 Million | 756.41 Million | 768.43 Million | 477.39 Million | 359.33 Million | 145.4 Million |
| Cash at end of period | 686.18 Million | 927.28 Million | 756.41 Million | 768.43 Million | 477.39 Million | 359.33 Million |
| Capital Expenditure | -21.68 Million | -101.96 Million | -425.57 Million | -221.29 Million | -48.99 Million | -23.36 Million |
| Effect of forex changes on cash | 7.04 Million | 40.1 Million | -14.41 Million | -27.86 Million | 4.48 Million | 8.09 Million |
| Net cash flow / Change in cash | -243.09 Million | 170.87 Million | -12.01 Million | 291.03 Million | 118.06 Million | 213.92 Million |
| Free Cash Flow | 1.06 Billion | 735.41 Million | -59.04 Million | 206.87 Million | 440.59 Million | 265.85 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 168.73 Million | 310.21 Million | 312.91 Million | 800.91 Million | -54.42 Million | 259.43 Million |
| Depreciation & Amortization | - | 18.46 Million | 18.46 Million | 61.74 Million | 8.63 Million | -47.66 Million |
| Deferred income taxes | 19.55 Million | - | - | -55.86 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -93.62 Million | - | -105.17 Million | -252.58 Million | 225.55 Million |
| Other non-cash items | -18.08 Million | -128.63 Million | 127.27 Million | 611.05 Million | 581.57 Million | -198.89 Million |
| Investing Cash Flow | 371.42 Million | 117 Million | -343.59 Million | -848.38 Million | -516.33 Million | 206.17 Million |
| Investments in PPE | -3.52 Million | -8.84 Million | -1.5 Million | -21.68 Million | -2.97 Million | -5.3 Million |
| Acquisitions | 21 Thousand | 30.6 Thousand | - | 2.75 Million | -5.95 Million | 105.92 Thousand |
| Investment purchases | -900 Million | -1.1 Billion | -1.38 Billion | -3.82 Billion | -1.36 Billion | -631.39 Million |
| Sales/Maturities of investments | 1.27 Billion | 1.23 Billion | 1.04 Billion | 2.99 Billion | 851.99 Million | 846.23 Million |
| Other Investing Activities | - | 30.6 Thousand | -338.08 Million | 1.00 | 3.53 Million | -3.46 Million |
| Financing Cash Flow | -677.62 Million | -197.94 Million | 259.27 Million | -485.89 Million | -263.47 Million | -175.5 Million |
| Debt repayment | -358.77 Million | -15.53 Million | -261.56 Million | -13.77 Million | -255.48 Million | -97 Million |
| Dividends payments | - | -182.4 Million | -2.28 Million | -482.98 Million | -2.78 Million | -301.6 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -318.84 Million | -182.4 Million | -2.28 Million | 10.86 Million | -5.2 Million | 223.1 Million |
| Accounts receivables | - | -78.25 Million | - | -237.88 Million | -237.88 Million | 225.09 Million |
| Accounts payables | - | - | - | 147.4 Million | - | -20.02 Million |
| Inventory | - | -15.37 Million | - | -16.55 Million | -16.55 Million | 467 Thousand |
| Other working capital | - | - | - | 1.86 Million | 1.86 Million | 20.02 Million |
| Cash at beginning of period | 1.12 Billion | 2.17 Billion | 686.18 Million | 929.28 Million | 1.68 Billion | 932.19 Million |
| Cash at end of period | 1.61 Billion | 1.12 Billion | 2.17 Billion | 686.18 Million | 686.18 Million | 1.18 Billion |
| Capital Expenditure | -3.52 Million | -8.84 Million | -1.5 Million | -21.68 Million | -2.97 Million | -5.3 Million |
| Effect of forex changes on cash | - | -1.34 Million | 2.04 Million | 7.04 Million | -8.03 Million | -14.48 Million |
| Net cash flow / Change in cash | 493.93 Million | -1.04 Billion | 1.48 Billion | -243.09 Million | -999.49 Million | 254.61 Million |
| Free Cash Flow | 166.67 Million | 154.26 Million | 438.68 Million | 1.06 Billion | 280.23 Million | 233.12 Million |
LABS
TBEV
MVP
CDBDF
UPPR
TANA